AdvanCell
Updated: July 15, 2026
Founder Andrew Adamovich
Country: Australia | Funding: $453M (+)
Founded: 2019
Website: https://www.advancell.com.au/
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. Its lead asset, ADVC001, is currently in a phase 2 trial for metastatic prostate cancer. It's a lutetium-based alpha emitter, which breaks both strands of DNA, a wound much harder for cancer to bounce back from. It can be delivered, lead to double-stranded DNA breaks of the tumor cells in a highly targeted way, and then quickly be gone, which could minimize the accumulation in surrounding healthy tissues.
Founded: 2019
Website: https://www.advancell.com.au/
AdvanCell is a clinical-stage radiopharmaceutical company that develops novel cancer therapeutics. Its lead asset, ADVC001, is currently in a phase 2 trial for metastatic prostate cancer. It's a lutetium-based alpha emitter, which breaks both strands of DNA, a wound much harder for cancer to bounce back from. It can be delivered, lead to double-stranded DNA breaks of the tumor cells in a highly targeted way, and then quickly be gone, which could minimize the accumulation in surrounding healthy tissues.
